Skip to main content
OpenTrials

Clinical trial condition

Lymphatic Diseases

Explore clinical trials studying Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

8,995 public trials 1,838 recruiting studies
Refine in advanced search Browse all conditions

Lymphatic Diseases trial results

Active, not recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • UZ Gent Ghent, Belgium
  • Aarhus Universitetshospital Skejby Aarhus N, Denmark
  • Rigshospitalet København Ø, Denmark
  • Odense Universitetshospital Odense C, Denmark
View all 19 locations
View Trial Details
Active, not recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Local Institution - 0014 Mobile, Alabama, United States
  • Local Institution - 0477 Anchorage, Alaska, United States
  • Local Institution - 0452 Phoenix, Arizona, United States
  • Local Institution - 0342 San Francisco, California, United States
View all 325 locations
View Trial Details
Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute Louisville, Kentucky, United States
  • John Theurer Cancer Center Hackensack, New Jersey, United States
  • Novant Health Charlotte, North Carolina, United States
  • Institut - Jules Bordet Anderlecht, Belgium
View all 88 locations
View Trial Details
Active, not recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • The Oncology Institute (TOI) Clinical Research Cerritos, California, United States
  • Norton Cancer Institute, St. Matthews Louisville, Kentucky, United States
View all 38 locations
View Trial Details
Active, not recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • UACC Arizona Tucson, Arizona, United States
  • University of California San Francisco San Francisco, California, United States
  • University of California Los Angeles (UCLA) Santa Monica, California, United States
  • Boca Raton Cancer Research Medical Center Plantation, Florida, United States
View all 175 locations
View Trial Details
Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +80 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 174 locations
View Trial Details

Related conditions